Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. The initial ...

Following these transactions, Schneider's direct ownership in Ionis Pharmaceuticals (NASDAQ:IONS) stands at 58,508 shares. Ionis Pharmaceuticals, based in Carlsbad, California, is a biotechnology ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $51.6, a high estimate of $64.00, and a low estimate of $39.00. A decline of 4.44% from the ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), retaining the price target of $68.00. Jason Gerberry has given his ...

HC Wainwright reiterated their buy rating on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) in a research report released on Tuesday morning,Benzinga reports. HC Wainwright ...

Review Ionis Pharmaceuticals Inc (IONS:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. Ionis Pharmaceuticals’s revenue was up 10.9% on a year-over-year basis.

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target of $59.00. Yaron Werber’s rating is based ...